Dominic Stone
Glucose-6-phosphate dehydrogenase (G6PD) is the most common deficient enzyme in the world, affecting more than 400 million people. G6PD deficiency is a genetically inherited condition causing haemolytic anemia, which may lead to multi-organ failure and mortality. G6PD deficiency has been linked to an increased risk of cardiovascular disease (CVD) and heart failure. Studies suggest that G6PD deficiency may cause oxidative stress and accelerate the development of heart failure by increasing reactive oxygen species-generating enzymes. However, there is limited clinical evidence, and the impact of G6PD deficiency on the pathophysiology of CVD is not yet fully understood.
| Characteristics | Values |
|---|---|
| Glucose-6-phosphate dehydrogenase (G6PD) | The most common deficient enzyme in the world |
| G6PD deficiency | Affects over 400 million people worldwide |
| G6PD deficiency impact on cardiovascular disease | Poorly understood |
| G6PD deficiency and oxidative damage | G6PD-deficient cells do not cope well with oxidative damage |
| G6PD deficiency and hypertension | Limited clinical evidence indicates a link |
| G6PD deficiency and heart disease | May decrease the risk of heart disease and cardiovascular-associated deaths |
| G6PD and NADPH | G6PD catalyzes the conversion of G6P to 6-phosphogluconolactone and the formation of NADPH from NADP+ |
| G6PD and myocardial infarction | Myocardial infarction resulted in left ventricular dilation and dysfunction in both wild-type and G6PDX mice |
| G6PD and red blood cells | Protects red blood cells from the effects of potentially harmful molecules called reactive oxygen species |
| G6PD deficiency and hemolytic anemia | Most common medical problem associated with G6PD deficiency |
| G6PD deficiency and malaria | People with a G6PD variant may be partially protected against malaria |
| G6PD and heart muscle | Glucose 6-phosphate accumulates via phosphoglucose isomerase inhibition in heart muscle |
Explore related products
What You'll Learn
Glucose-6-phosphate dehydrogenase (G6PD) deficiency
Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme found in the cytoplasm of all cells in the body. It is a "housekeeping" enzyme that plays a critical role in preventing cellular damage from reactive oxygen species (ROS) by providing substrates to prevent oxidative damage. G6PD is the most common enzyme deficiency in humans, affecting over 400 million people worldwide. The deficiency is caused by a mutation in the G6PD gene, resulting in low levels of functional glucose-6-phosphate dehydrogenase and NADPH. This depletion of NADPH, an antioxidant, makes red blood cells more susceptible to destruction from oxidative stress, which can lead to acute hemolytic anemia.
G6PD deficiency is inherited as an X-linked recessive disorder, with males being more commonly affected than females due to X-linked inheritance. It is most prevalent in tropical and subtropical areas, and individuals of African, Mediterranean, or Asian descent are at a higher risk. The geographic prevalence of the disorder correlates with the historical distribution of malaria, as G6PD deficiency confers partial protection against uncomplicated malaria.
While most patients with G6PD deficiency are asymptomatic, some may experience neonatal jaundice and acute hemolytic anemia. Certain drugs, infections, and exposure to plants like fava beans can trigger episodes of hemolysis in individuals with G6PD deficiency. Additionally, G6PD deficiency has been associated with an increased risk of cardiovascular disease and may moderately accelerate the development of heart failure by increasing redox stress. However, limited clinical evidence also suggests a protective role of G6PD deficiency in decreasing the risk of heart disease and cardiovascular-associated deaths.
The impact of G6PD deficiency on cardiovascular disease is not yet fully understood, and further research is needed to elucidate the complex relationship between G6PD deficiency and heart health. Nonetheless, it is clear that G6PD plays a crucial role in maintaining cellular health, and its deficiency can have significant implications for affected individuals.
Muscle Strain: Numbness and Other Surprising Symptoms
You may want to see also
Explore related products
G6PD and oxidative stress
Glucose-6-phosphate dehydrogenase (G6PD) is the most common deficient enzyme in the world, affecting over 400 million people. G6PD is involved in the rate-limiting step of the pentose phosphate pathway (PPP), which generates reduced nicotinamide adenine dinucleotide phosphate (NADPH). NADPH is crucial for the production of reduced glutathione, which protects against oxidative damage. G6PD-deficient cells struggle to cope with oxidative stress, and the deficiency is associated with increased oxidative stress and the risk of cardiovascular disease.
G6PD deficiency decreases myocardial antioxidant capacity, exacerbating the adverse cardiac effects of acute oxidative stress, such as ischemia-reperfusion injury. In G6PD-deficient mice models, acute ischemia-reperfusion injury increased G6PD activity, and the deficiency resulted in greater impairment in relaxation and pressure development after injury compared to wild-type mice. The exacerbated impairments were rescued by antioxidant treatment, demonstrating the critical role of antioxidant defenses in G6PD deficiency.
In failing hearts, G6PD is upregulated and generates NADPH, which is used by the glutathione pathway to remove reactive oxygen species. However, G6PD deficiency might prevent heart failure by decreasing NADPH and reactive oxygen species production. Studies in G6PD-deficient mice models have shown that G6PD deficiency results in greater left ventricular dilation and wall thinning compared to wild-type mice. These findings suggest that G6PD deficiency increases redox stress and moderately accelerates the development of heart failure.
Additionally, G6PD expression can be abnormally elevated in various cancers, and it may act as a regulator of viral replication and vascular smooth muscle function. The activation of G6PD through treatments such as benfotiamine has been found to decrease infarct size and oxidative stress, improve survival, and enhance functional parameters in the heart. Overall, while G6PD deficiency is associated with increased oxidative stress, the activation of G6PD may have beneficial effects in heart failure.
Cardio and Muscle Loss: How Much is Too Much?
You may want to see also
Explore related products
G6PD deficiency and heart failure
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is the most common enzyme deficiency in humans, affecting over 400 million people worldwide. G6PD deficiency decreases myocardial antioxidant capacity, which may exacerbate the adverse cardiac effects of acute oxidative stress, such as ischemia-reperfusion injury.
G6PD deficiency has been linked to an increased risk of cardiovascular disease (CVD) and coronary heart disease. Studies suggest that G6PD deficiency may be a risk factor for CVD, with higher blood pressure levels observed in those with the deficiency. G6PD is involved in the rate-limiting step of the pentose phosphate pathway, which generates reduced nicotinamide adenine dinucleotide phosphate (NADPH). In red blood cells (RBCs), the NADPH/G6PD pathway is the only source for recycling reduced glutathione, which provides protection from oxidative stress.
G6PD deficiency can put stress on RBCs, which may be further exacerbated by certain pathophysiological conditions and drug treatments, leading to hemolytic anemia and, in severe cases, multi-organ failure and mortality. G6PD deficiency may also increase the risk of diabetes and renal failure.
In terms of heart failure, G6PD deficiency has been shown to moderately accelerate its development. G6PD is upregulated in failing hearts, generating NADPH that is used by the glutathione pathway to remove reactive oxygen species (ROS). G6PD deficiency might prevent heart failure by decreasing NADPH and ROS production. This has been supported by studies in mouse models of human G6PD deficiency, which showed that G6PD-deficient mice had significantly greater end-diastolic volume and wall thinning compared to wild-type mice after myocardial infarction.
Overall, while G6PD deficiency may offer some protection against CVD and coronary heart disease, it can also increase the risk of heart failure by exacerbating oxidative stress and impairing cardiac function. However, more research is needed to fully understand the impact of G6PD deficiency on cardiovascular health and to develop effective treatments for patients with G6PD deficiency and heart failure.
Muscle Soreness and Shivering: What's the Connection?
You may want to see also
Explore related products
G6PD deficiency and myocardial infarction
Glucose-6-phosphate dehydrogenase (G6PD) is the most common enzyme deficiency in humans, affecting over 400 million people worldwide. G6PD deficiency is an X-linked genetic condition that primarily affects red blood cells (RBCs) and can cause haemolytic anemia. While the impact of G6PD deficiency on cardiovascular disease is not yet fully understood, studies suggest that it may be a risk factor for cardiovascular disease (CVD) and could play a role in the development of heart failure.
G6PD is an essential enzyme in the pentose phosphate pathway (PPP), which is responsible for generating reduced nicotinamide adenine dinucleotide phosphate (NADPH). NADPH is crucial for maintaining glutathione levels and protecting cells from oxidative stress. In G6PD-deficient individuals, the reduced glutathione levels can lead to an impaired ability to cope with oxidative damage.
Several studies have investigated the impact of G6PD deficiency on myocardial infarction, which is a leading cause of heart failure. In a mouse model of myocardial infarction, G6PD-deficient mice (G6PDX) exhibited greater left ventricular dilation and dysfunction compared to wild-type mice. Specifically, G6PD deficiency resulted in significantly greater end-diastolic volume and wall thinning. Additionally, pressure overload induced by transverse aortic constriction (TAC) caused greater left ventricular dilation in G6PDX mice, indicating that G6PD deficiency may contribute to adverse cardiac remodelling.
Furthermore, G6PD-deficient myocardium struggles to compensate for increased oxidative stress, as seen in experiments with acute ischemia-reperfusion injury. The G6PD-deficient hearts displayed greater impairment in relaxation and pressure development compared to wild-type hearts. These impairments were rescued by antioxidant treatment, highlighting the critical role of antioxidants in mitigating the effects of G6PD deficiency.
While the exact mechanisms remain to be fully elucidated, some studies suggest that G6PD deficiency might protect against coronary heart disease and decrease the risk of cardiovascular-associated deaths. This protective effect is possibly due to a decrease in cholesterol synthesis. However, conflicting evidence also exists, with some studies showing that G6PD deficiency can worsen cardiac remodelling and increase systolic dysfunction, fetal gene expression, and hypertrophy. Therefore, further research is needed to comprehensively understand the impact of G6PD deficiency on myocardial infarction and heart failure.
Small Fiber Neuropathy: Muscle Twitching Explained
You may want to see also
Explore related products
G6PD deficiency and hypertension
Glucose-6-phosphate dehydrogenase (G6PD) is the most common enzyme deficiency in humans, affecting over 400 million people worldwide. G6PD deficiency decreases vascular superoxide and atherosclerotic lesions and protects against coronary heart disease. However, it may also increase the risk of cardiovascular disease (CVD) and heart failure.
G6PD is involved in the rate-limiting step of the pentose phosphate pathway (PPP), which generates reduced nicotinamide adenine dinucleotide phosphate (NADPH). NADPH is a co-factor in the synthesis of nitric oxide (NO). G6PD-deficient cells do not cope well with oxidative damage, and G6PD deficiency decreases myocardial antioxidant capacity. This may exacerbate the adverse cardiac effects of acute oxidative stress, such as ischemia-reperfusion injury.
G6PD deficiency has been linked to an increased risk of hypertensive cardiovascular disease, including pulmonary hypertension. It is also associated with an increased risk of hypertension in specific ethnic groups. For example, the incidence of G6PD deficiency among Afro-Caribbeans is 11-14%, and this group also has the highest incidence of CVD and a two- to threefold increased risk of stroke compared to other ethnic groups. Additionally, there are 200 million people worldwide with red cell X-linked chromosome defects who are at greater risk of developing hypertension with the persistent ingestion of refined carbohydrates.
Furthermore, G6PD deficiency may reduce the vascular response to angiotensin II (Ang II), a potent vasoconstrictor. Ang II increases blood pressure, and G6PD deficiency may blunt this increase. However, G6PD-deficient mice displayed a greater impairment in relaxation and pressure development after injury compared to wild-type mice.
In summary, G6PD deficiency has been associated with an increased risk of hypertension, particularly in specific ethnic groups and those with red cell X-linked chromosome defects who consume refined carbohydrates. It may also reduce the vascular response to Ang II and blunt blood pressure increases. However, G6PD deficiency has also been linked to a protective effect against coronary heart disease, possibly by decreasing the risk of heart disease and cardiovascular-associated deaths. Further research is needed to fully understand the complex role of G6PD deficiency in hypertension and cardiovascular health.
Relieving Statin-Induced Muscle Pain: Natural Approaches
You may want to see also
Frequently asked questions
Glucose-6-phosphate dehydrogenase is the most common deficient enzyme in the world, affecting over 400 million people worldwide. It is involved in the rate-limiting step of the pentose phosphate pathway, which generates reduced nicotinamide adenine dinucleotide phosphate (NADPH).
G6PD deficiency is a risk factor for cardiovascular disease (CVD) and can lead to heart failure. In failing hearts, G6PD is upregulated and generates NADPH, which is used by the glutathione pathway to remove reactive oxygen species. G6PD deficiency may prevent heart failure by decreasing NADPH and reactive oxygen species production.
G6PD deficiency puts stress on red blood cells (RBC), which can cause hemolytic anemia and eventually lead to multi-organ failure and mortality. Subjects with this condition may experience episodes of hemolysis after infections, the assumption of certain drugs, or exposure to certain plants.
